74 related articles for article (PubMed ID: 22486580)
1. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.
Bares M; Novak T; Kopecek M; Stopkova P; Cermak J; Kozeny J; Höschl C
Int J Psychiatry Clin Pract; 2013 Feb; 17(1):35-43. PubMed ID: 22486580
[TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
3. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
4. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
[TBL] [Abstract][Full Text] [Related]
5. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study.
Bares M; Novak T; Kopecek M; Stopkova P; Sos P
Neuro Endocrinol Lett; 2009; 30(6):723-8. PubMed ID: 20038931
[TBL] [Abstract][Full Text] [Related]
6. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study.
Bares M; Novak T; Kopecek M; Stopkova P; Höschl C
Int J Psychiatry Clin Pract; 2010 Nov; 14(4):303-8. PubMed ID: 24917443
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Chen SJ; Hsiao YL; Shen TW; Chen ST
J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
[TBL] [Abstract][Full Text] [Related]
16. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
20. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
